Sign in
Not yet recruitingPhase 1/2

Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors

Key facts

Who runs it
Qilu Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
558 people, planned
Started
15 Nov 2026
Expected to end
15 Nov 2029
Type of study
Interventional, 6 groups
Treatments tested
  • QLS5133; Lenvatinib mesylate
  • QLS5133; QL2107; Lenvatinib mesylate
  • QLS5133; Bevacizumab
  • QLS5133; Platinum; Bevacizumab
  • QLS5133; Olaparib; Bevacizumab
  • QLS5133; QL2107; Bevacizumab
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • 1. Histologically or cytologically confirmed advanced solid tumors, with specific tumor type and prior treatment requirements per each cohort
  • 2. Measurable disease per RECIST v1.1 (except Cohorts 3B-1, 3B-2, and 5B)
  • 3.Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • 4.Adequate organ function
  • 5.Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to NCI-CTCAE v6.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral

Who cannot take part

  • 1.Prior treatment with CDH6-targeted agents or topoisomerase I inhibitors (including ADCs)
  • 2.Prior treatment with immune checkpoint inhibitors (for Cohorts 2 and 6 only)
  • 3.Prior Grade 4 or persistent ≥ 4-week Grade 3 immune-related AEs from immune checkpoint inhibitors
  • 4.Prior systemic anti-tumor therapy (for Cohorts 1B-2 and 2B-2 only)
  • 5.Recent anti-tumor therapy within specified washout periods (small molecules: 2 weeks; biologics/chemotherapy: 4 weeks; mitomycin/nitrosoureas: 6 weeks)
  • 7. Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
  • 8.History of significant cardiac disease, or poorly controlled diabetes mellitus
  • 9.History of recurrent autoimmune diseases
  • 10. History of a second primary malignancy
  • 11.Be allergic to any component of QLS5133 or its excipients
  • 6.Active or symptomatic CNS metastases or leptomeningeal carcinomatosis

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Clear cell renal cell carcinoma or ovarian cancer

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5133 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion.

Read full original descriptionShow less

The main questions it aims to answer are:

* In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5133 combination therapy, and what are the recommended dose(s) for expansion? * In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5133 combination therapy at the selected dose(s) in participants with specific tumor types?

Participants will:

* Be enrolled in sequential cohorts to receive QLS5133 in combination with other anticancer agents. * Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.

The 6 groups in the trial

  • Arm 1Treatment being tested

    QLS5133 in combination with lenvatinib mesylate

    Treatment: QLS5133; Lenvatinib mesylate

  • Arm 2Treatment being tested

    QLS5133 in combination with lenvatinib mesylate plus QL2107

    Treatment: QLS5133; QL2107; Lenvatinib mesylate

  • Arm 3Treatment being tested

    QLS5133 in combination with bevacizumab

    Treatment: QLS5133; Bevacizumab

  • Arm 4Treatment being tested

    QLS5133 in combination with platinum-based therapy with or without bevacizumab, followed by QLS5133 alone or in combination with bevacizumab

    Treatment: QLS5133; Platinum; Bevacizumab

  • Arm 5Treatment being tested

    QLS5133 in combination with olaparib with or without bevacizumab

    Treatment: QLS5133; Olaparib; Bevacizumab

  • Arm 6Treatment being tested

    QLS5133 in combination with QL2107 with or without bevacizumab

    Treatment: QLS5133; QL2107; Bevacizumab

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenous QLS5133 Combination Therapy in Participants With Advanced Solid Tumors
Criteria questions
Built from NCT07933419, who can take part
Record updated
12 November 2026